can you explain your valuation? When I remove all non-IS sales I get to ~$10. I don't think that is even realistic, so in my model downside is only a few bucks at most on another Aetna headline.
Questcor Poised To Rally To $80 On Continued Sales Growth [View article]
Yes, my call was exactly the wrong call (at least as of today). I've never seen anything like this. What is difficult for me to comprehend is that the impact of the recent revelations is still a matter of speculation and that we are evaluating a company and management team that has historically delivered for investors and yet are not getting any benefit of the doubt.
Questcor Poised To Rally To $80 On Continued Sales Growth [View article]
I don't think there will be a material change. The Aetna coverage decision is ambiguous and looks like many other coverage policies that do cover Acthar.
Rockwell Medical Overvalued Based On Significant Risk [View article]
Perhaps you're confused or it was unclear in the article...
"This also assumes that RMTI first gains FDA approval to market Calcitriol - the company has recently noted that they are currently in the process of getting their manufacturing facility approved"
Rockwell acquired Calcitriol along with an APPROVED ANDA... no need for FDA approval... they are simple checking off on manufacturing stability, which is standard
Questcor Poised To Rally To $80 On Continued Sales Growth [View article]
Wow!! During August 2012, Questcor shipped a total of 2,190 vials of Acthar (this is versus 1,650 in July and prior record high of 1,800 in June). NS and DM/PM look great. I think we see $80 sooner than later.....
Arena, Orexigen And Vivus: Obesity Sector Overview - Part 2 [View article]
Some valid criticism, others not. Tough to predict how this space will unfold. I'm going to wait until the launches and then start some physician surveys. Until then, I'm on the sidelines.
Physician Survey Results On Lomitapide And Mipomersen Support Our Thesis [View article]
I have not talked to any cardiologists, but my gut feeling is these incredibly severe patients are seeing a relatively small number of experts (lipidologists). I expect the company to need a very small sales force and for them to have a very attractive P&L, much like Alexion. Awareness of the product is already high and the company has stated that they are identifying candidates for therapy now. My expectation is the stock runs into a panel/PDUFA and if approved goes up 2-3x from where it is now.
Watching The Prescription Data For 4 Pharma Companies [View article]
I think you should expect utter failure. Sales are stuck at ~$1MM per month. I hope the so-called upward sales trend the CEO is referring to exists because I think the debt holders will hold him to the fire if he is misleading them.
Watching The Prescription Data For 4 Pharma Companies [View article]
I think you should expect utter failure. Sales are stuck at ~$1MM per month. I hope the so-called upward sales trend the CEO is referring to exists because I think the debt holders will hold him to the fire if he is misleading them. Andrew
Physician Survey Results On Lomitapide And Mipomersen Support Our Thesis [View article]
That is not the conclusion. The conclusion is docs prefer lomitapide over mipo. A QD oral is better than an weekly SC injection. Efficacy and tolerability are both better for lomitapide - hence the physician preference. Its not a stretch by any means.
Questcor: What's Really Changed? [View article]
Questcor Poised To Rally To $80 On Continued Sales Growth [View article]
Questcor Poised To Rally To $80 On Continued Sales Growth [View article]
Rockwell Medical Overvalued Based On Significant Risk [View article]
"This also assumes that RMTI first gains FDA approval to market Calcitriol - the company has recently noted that they are currently in the process of getting their manufacturing facility approved"
Rockwell acquired Calcitriol along with an APPROVED ANDA... no need for FDA approval... they are simple checking off on manufacturing stability, which is standard
Questcor Poised To Rally To $80 On Continued Sales Growth [View article]
Arena, Orexigen And Vivus: Obesity Sector Overview - Part 2 [View article]
Physician Survey Results On Lomitapide And Mipomersen Support Our Thesis [View article]
Watching The Prescription Data For 4 Pharma Companies [View article]
Watching The Prescription Data For 4 Pharma Companies [View article]
Andrew
Watching The Prescription Data For 4 Pharma Companies [View article]
Physician Survey Results On Lomitapide And Mipomersen Support Our Thesis [View article]
Physician Survey Results On Lomitapide And Mipomersen Support Our Thesis [View article]
Physician Survey Results On Lomitapide And Mipomersen Support Our Thesis [View article]
Watching The Prescription Data For 4 Pharma Companies [View article]
Watching The Prescription Data For 4 Pharma Companies [View article]